Antibody response to culture filtrate antigens of Mycobacterium tuberculosis during and after treatment of tuberculosis patients.

Int J Tuberc Lung Dis

Instituto Nacional de Enfermedades Respiratorias 'Emilio Coni', ANLIS 'Carlos Malbran', Santa Fe, Argentina.

Published: June 2000

Setting: Many authors have shown rising titres of anti-mycobacterial antibodies after a few months of anti-tuberculosis treatment. This humoral response might persist for years, making the discrimination between current and old disease difficult.

Objective: Characterisation of the humoral response to culture filtrates of Mycobacterium tuberculosis before and after treatment of tuberculous patients in order to identify those antigens that could provide information about disease activity.

Methods: Anti-mycobacterial IgG response was determined during and after treatment of tuberculous patients by ELISA and immunoblot. Serum was taken from 71 active tuberculous patients (59 newly acquired and 12 relapse), 15 old tuberculous patients and 45 nontuberculous control subjects.

Results: By ELISA, antibody response increased after 2 months of treatment. After chemotherapy was completed, the estimated number of antibodies remained at the same level. The level of specific antibodies in patients seems to reach the same level as that of control subjects 3 years after initiation of treatment. In Western blot, although each patient serum had its own characteristic banding pattern, differences between tuberculous patients and control subjects were found in the area below 20 kDa. Serum from tuberculous patients showed high levels of antibodies at the 14 kDa region. After the beginning of treatment, the intensity of the 14 kDa region band and the percentage of positive recognition tended to decrease. Therefore, one year after initiation of treatment, only seven of 13 cases who demonstrated anti-mycobacterial antibodies in ELISA revealed a mild but still positive reaction at the 14 kDa region; this reactivity disappeared 2 years after initiation of chemotherapy.

Conclusions: The 14 kDa region antigen seems to induce a humoral response that evolves in relation with the disease activity.

Download full-text PDF

Source

Publication Analysis

Top Keywords

tuberculous patients
24
kda region
16
humoral response
12
antibody response
8
response culture
8
mycobacterium tuberculosis
8
treatment
8
tuberculosis treatment
8
patients
8
anti-mycobacterial antibodies
8

Similar Publications

Background: Although existing disease preparedness and response frameworks provide guidance about strengthening emergency response capacity, little attention is paid to health service continuity during emergency responses. During the 2014 Ebola outbreak, there were 11,325 reported deaths due to the Ebola virus and yet disruption in access to care caused more than 10,000 additional deaths due to measles, HIV/AIDS, tuberculosis, and malaria. Low- and middle-income countries account for the largest disease burden due to HIV, tuberculosis, and malaria and yet previous responses to health emergencies showed that HIV, tuberculosis, and malaria service delivery can be significantly disrupted.

View Article and Find Full Text PDF

Objective: The demanding nature and psychosocial burdens of directly observed treatment (DOT) have opened a path to alternative strategies such as video-observed therapy (VOT), which offers comparable treatment outcomes and patient satisfaction while potentially saving time and reducing costs. The objective of this study was to evaluate the perceptions and experiences of patients and health care professionals regarding DOT and other treatment strategies implemented in Portugal.

Methods: Patients with a confirmed diagnosis of tuberculosis, treated at the Vila Nova de Gaia Outpatient Tuberculosis Centre in the last two years, were asked to complete a brief questionnaire, as were health care professionals working in the northern region of Portugal.

View Article and Find Full Text PDF

Bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) for multidrug- or rifampin-resistant tuberculosis: a systematic review.

J Bras Pneumol

January 2025

. Instituto de Doenças do Tórax - IDT - Faculdade de Medicina, Universidade Federal do Rio de Janeiro - UFRJ - Rio de Janeiro (RJ) Brasil.

Objective: To evaluate the available evidence comparing the use of the bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) regimen for 6 months with that of standard-of-care regimens for patients with multidrug-resistant or rifampin-resistant tuberculosis (MDR/RR-TB).

Methods: This was a systematic review of clinical trials comparing the use of the BPaLM regimen with the standard of care in patients with MDR/RR-TB. The main outcome measure was an unfavorable endpoint (a composite of death, treatment failure, treatment discontinuation, loss to follow-up, and recurrence), and secondary outcome measures included adverse events and serious adverse events.

View Article and Find Full Text PDF

Introduction: Tuberculosis (TB) is one of the major global health challenges and concerns. Despite the availability of effective treatment in Malaysia, it remained a consistently high notification rate of TB cases. The objective of this study was to determine the proportion of successful TB treatment outcomes and its determinants among TB with comorbidities patients in Negeri Sembilan, Malaysia.

View Article and Find Full Text PDF

Introduction: Despite the availability of highly effective treatment for tuberculosis (TB), patients with TB may experience a relapse, which can be either a result of the disease reactivating or a new episode induced by reinfection. In Malaysia, there has been a noticeable rise in relapse TB cases, with a substantial rate of unsuccessful treatment outcomes among this population. This study seeks to examine the trends of unsuccessful treatment outcomes in relapse TB patients and explore how factors such as sociodemographic characteristics, TB disease profile, TB treatment profile, and comorbidities contribute to the outcomes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!